CTOs on the Move

RubrYc Therapeutics

www.rubryc.com

 
RubrYc Therapeutics is a biotechnology company that integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody-based drugs.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

RubrYc Therapeutics raised $10M on 04/11/2018

Similar Companies

Third Wave Technologies

Third Wave Technologies, Inc. is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spring Works

Spring Works is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CAPARIO

CAPARIO is a Santa Ana, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ImmunoGen

Targeting a better life for people with cancer is why we get up in the morning. It`s not enough to disrupt the progress of someone`s cancer; we want to keep cancer from disrupting someone`s life. That`s why everything we do is about developing the most precise, targeted cancer therapies. We believe this is the best way to get people back to their lives—back to living today, tomorrow, and beyond. Because for us, targeting a better now is the only thing that matters. ImmunoGen is a leader in developing antibody-drug conjugates (ADCs). Our lead product candidate, mirvetuximab soravtansine, is a first-in-class folate receptor alpha (FRα)-targeting ADC with multiple studies underway in ovarian cancer. Our second pivotal program, IMGN632, is a CD123-targeting ADC being studied as a monotherapy in BPDCN and in combination in AML. Our earlier-stage assets in development are IMGC936, an ADAM9-targeting ADC in co-development with MacroGenics, and IMGN151, our next generation anti-folate receptor alpha ADC.

BioMarker Strategies

BioMarker Strategies is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.